Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

BACKGROUND: The objective of the IMPROVE study was patients’ preference for either endocrine-based therapy or combined chemo- and anti-angiogenic therapy in advanced HR-positive/HER2-negative breast cancer. METHODS: In this randomized, cross-over phase IV study, 77 patients were recruited in 26 site...

Descripción completa

Detalles Bibliográficos
Autores principales: Decker, Thomas, Söling, Ulrike, Hahn, Antje, Maintz, Christoph, Kurbacher, Christian Martin, Vehling-Kaiser, Ursula, Sent, Dagmar, Klare, Peter, Hagen, Volker, Chiabudini, Marco, Falkenstein, Julia, Indorf, Martin, Runkel, Eva, Potthoff, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137210/
https://www.ncbi.nlm.nih.gov/pubmed/32252684
http://dx.doi.org/10.1186/s12885-020-06747-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137210/
https://www.ncbi.nlm.nih.gov/pubmed/32252684
http://dx.doi.org/10.1186/s12885-020-06747-y

Ejemplares similares